ZIDOVUDINE
LOE ApproachingNDAORALTABLET
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZIDOVUDINE by Aurobindo Pharma is [see microbiology ( )]. Approved for combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2009.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Zidovudine is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved for HIV-1 treatment in combination with other antiretroviral agents. It works by inhibiting reverse transcriptase, blocking viral replication in HIV-infected cells. This foundational antiretroviral has been a cornerstone of HIV therapy since the 1980s.
LOE Approaching
Declining commercial relevance as LOE approaches; team consolidation and transition roles likely as generic penetration increases.
Mechanism of Action
[see Microbiology ( )].
Worked on ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.